Natural killer cells, multiple myeloma, and daratumumab : a love-hate relationship by Chrobok, Michael
  
From the Department of Medicine, Huddinge 
Karolinska Institutet, Stockholm, Sweden 
NATURAL KILLER CELLS, MULTIPLE MYELOMA, AND 
DARATUMUMAB 
- A LOVE-HATE RELATIONSHIP 
Michael Chrobok 
 
Stockholm 2019 
 
  
 
All previously published papers were reproduced with permission from the publisher. 
Published by Karolinska Institutet. 
Front cover modified from: 
https://www.northshore.org/globalassets/cancer/immunotherapy-cell.jpg 
Printed by E-Print, AB 
© Michael Chrobok, 2019 
ISBN 978-91-7831-401-0 
  
NATURAL KILLER CELLS, MULTIPLE MYELOMA, AND 
DARATUMUMAB 
- A LOVE-HATE RELATIONSHIP 
 
THESIS FOR DOCTORAL DEGREE (Ph.D.) 
By 
Michael Chrobok 
Principal Supervisor: 
Asst. Prof. Evren Alici 
Karolinska Institutet 
Department of Medicine, Huddinge 
Center for Hematology and 
Regenerative Medicine (HERM) 
 
Co-supervisors: 
Assoc. Prof Hareth Nahi 
Karolinska Institutet 
Department of Medicine, Huddinge 
Center for Hematology and 
Regenerative Medicine (HERM) 
 
Professor Petter Höglund 
Karolinska Institutet 
Department of Medicine, Huddinge 
Center for Hematology and 
Regenerative Medicine (HERM) 
 
Professor Katarina Le Blanc 
Karolinska Institutet 
Department of Laboratory Medicine 
Division of Clinical Immunology and  
Transfusion Medicine 
 
Carin Dahlberg 
Karolinska Institutet 
Department of Medicine, Huddinge 
Center for Hematology and 
Regenerative Medicine (HERM) 
Opponent: 
Professor Torsten Tonn 
Technische Universität Dresden 
Medical Faculty Carl-Gustav-Carus 
Transfusion Medicine 
 
 
Examination Board: 
Assoc. Prof. Helen Kaipe 
Karolinska Institutet 
Department of Laboratory Medicine 
Clinical Research Center 
 
 
Assoc. Prof. Fredrik Bergh Thorén 
University of Gothenburg 
Department of Infectious Diseases 
Institute of Biomedicine 
 
 
Assoc. Prof. Helene Hallböök  
Uppsala University 
Department of Medical Sciences,  
Hematology  
 
 

  
 
 
 
 
 
 
 
“I’ve gone on record to say that by 2025, cancer researchers will have developed curative 
therapeutic approaches for most if not all cancers.” 
 
Gary Gilliland 
 President and Director, Fred Hutchinson Cancer Research Center (FHCRC) 
2018 
 
  
  
 
 
  
ABSTRACT 
 
Multiple myeloma is a treatable, but not yet curable, malignant plasma cell disease. Over the 
last decades, the overall survival time of multiple myeloma patients has constantly increased 
thanks to improvements in conventional treatment methods like chemotherapy as well as 
autologous stem cell transplantation both in combination with novel drugs such as 
proteasome inhibitors or immunomodulatory drugs. However, no cure has been found yet. 
The only treatment that has the potential to cure multiple myeloma is allogeneic stem cell 
transplantation. However, it is seldomly used due to lack of donor availability, high risk for 
treatment related mortality and occurrence of graft versus host disease.  
 
The development of monoclonal antibody treatments for several cancer indications has 
shown great success. Lately, the emergence of Daratumumab, an anti-CD38 monoclonal 
antibody targeting plasma cells, has given a new hope for patients. Daratumumab has a minor 
direct effect on the MM cells but the majority of its effectiveness lies in utilizing the patient’s 
own immune cells to find and clear the body from MM cells. Several immune cells are known 
to be involved in this process such as natural killer cells, T cells and macrophages.  
Natural killer cells are experts in detecting virus infected or malignant transformed cells 
without the need for prior activation, and they are at the forefront of immune response 
against malignant cells and thus a promising option for cancer immunotherapy.  
 
In study I we could show that two heavily pretreated, triple refractory multiple myeloma 
patients, who received Daratumumab treatment and progressed, could be re-challenged 
with the same drug. We observed that the recurring multiple myeloma cells showed normal 
CD38 expression after a short treatment interruption. This made those patients eligible for 
a second line of Daratumumab treatment which has proven to be save. In both patients a 
partial response could be observed. Additionally, we reported that natural killer cells were 
depleted immediately after Daratumumab administration.  
 
The lack of natural killer cells in Daratumumab treated patients leaves them at risk for viral 
reactivation or bacterial infection. In study II we observed that an unusually high percentage 
of Daratumumab treated patients suffered from infectious complications, of which viruses 
of the herpes family were the most prominent. We monitored the immune status of those 
patients and their clinical parameters and one of our observations was that natural killer 
cells were reduced in general, but in particular the more mature natural killer cell population 
was depleted.  
These findings led us to the conclusion that combining monoclonal antibody treatment with 
adoptive cell transfer may have a synergistic effect and allow for better disease control.  
 
Producing natural killer cells in large quantities for clinical trials is challenging. One pivotal 
factor for robust cell expansion is serum, which is an undefined component with big batch 
to batch variation that will have a big impact on expansion rates und functionality of the 
cells. In order to circumvent this problem, we adapted the clinically used natural killer cell 
line NK-92 to serum-free conditions with inherited phenotype and growth rate. 
  
Additionally, we reported that serum-free NK-92 cells showed elevated functionality 
towards K562 cells after reintroduction of serum. We also performed RNA sequencing to 
compare serum-free cultured NK-92 cells with cells cultured under standard conditions to 
investigate the biological mechanisms involved in serum reduction.  
 
Altogether we propose that growing serum-free NK-92 cells is feasible and the reported 
protocol is robust, cheap and can be adapted for clinical grade production. Whether the 
combination of these cells with other advanced treatments will show additive or synergistic 
treatment outcomes for multiple myeloma patients, needs to be evaluated in future studies. 
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Ab antibody 
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TNF tumor necrosis factor 
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1 INTRODUCTION 
 
1.1 MULTIPLE MYELOMA 
 
Multiple myeloma (MM) is a malignant neoplasm of terminally differentiated, immunoglobulin 
(Ig)-producing, long-lived plasma cells. The hallmark feature of MM is the monoclonal 
expansion of plasma cells in the bone marrow with accompanying excessive production of 
monoclonal Ig that can be detected as a big spike in protein electrophoresis in the gamma 
zone coming from massive myeloma protein production; this spike is called "M spike" (Raab, 
Podar et al. 2009). MM is more prevalent in elderly population; the median age is 72 years 
in Sweden. The amount of heterogeneous chromosomal aberrations and numerous 
mutations in several genes are among the key elements of this disease; therefore MM is 
difficult to target therapeutically (Morgan, Walker et al. 2012).  
 
MM can start with an asymptomatic premalignant lesion stage that is called monoclonal 
gammopathy of undetermined significance (MGUS), progresses further to smoldering 
multiple myeloma (SMM) and eventually becomes symptomatic MM. The last step is also 
characterized by bone marrow (BM) infiltration and osteolytic lesions (Fairfield, Falank et al. 
2016). Typical symptoms of BM are net bone loss due to the skewing of the equilibrium 
between bone building osteoblasts and bone resorbing osteoclasts as well as increased 
fracture risk (Fowler, Edwards et al. 2011, Drake 2014). The signs for MM are often 
described by the acronym CRAB (elevated calcium, renal insufficiency, anemia, bone disease) 
while the transition between MGUS, SMM and MM is fluent and usually classified as having 
high serum or urinary monoclonal protein as well as 10-60% clonal plasma cells in the BM 
(Ghobrial and Landgren 2014, Rajkumar, Dimopoulos et al. 2014, Glavey and Ghobrial 
2015).  
 
MM cells very often have mutations in the RAS family (KRAS, NRAS, BRAF) or TP53 and 
DIS3 (Lohr, Stojanov et al. 2014). In many cases, the loss of the short arm of chromosome 
I (1p) and inactivation of p53 results in an abundance of Ig production (Furukawa and Kikuchi 
2015). Chromosomal aberrations are also very common in MM. Several subclones with 
different chromosomal aberrations can be found within the same patient and these 
subclones will most likely develop early on in the disease progression and might be 
responsible for relapse (de Mel, Lim et al. 2014, Prideaux, Conway O'Brien et al. 2014, 
Corre, Munshi et al. 2015). The Ig heavy chain gene is dominating in the most common 
chromosome translocations in MM such as: t(11;14), t(4;14), t(6;14), t(14;16), t(14;20) and 
the most abundant chromosomal gains and losses are: gain of 1q, loss of 1p, loss of 13/13q 
and loss of 17p (Anderson and Carrasco 2011, Prideaux, Conway O'Brien et al. 2014).  
 
1.2 NATURAL KILLER CELLS 
 
Cells that showed cytotoxic reactions to leukemia-associated antigens without previous 
sensitization were first reported by Rosenberg et al. in 1972 (Rosenberg, Herberman et al. 
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1972). Just 3 years later, the same cells were discovered by Rolf Kiessling and Eva Klein, 
who gave them their name natural killer (NK) cells; in parallel, researchers around Ronald 
Herberman discovered the same cell type (Herberman, Nunn et al. 1975, Herberman, Nunn 
et al. 1975, Kiessling, Klein et al. 1975, Kiessling, Klein et al. 1975). As NK cells can be 
"armed and ready to kill", they need rigorous mechanisms that control their activity and 
prevent unregulated killing (Bryceson, Chiang et al. 2011). While writing his doctoral thesis 
in 1981, Klas Kärre observed that some tumor cells downregulate major histocompatibility 
complex (MHC) class I during progression, which led to the proposal of the "missing-self" 
hypothesis. In 1986, Klas Kärre and Rolf Kiessling performed experiments where they 
detected that tumor cells that lack MHC class I were killed by NK cells while the same cell 
line expressing normal levels of MHC class I was not (Karre, Ljunggren et al. 1986, Ljunggren 
and Karre 1990). With the identification of inhibitory receptors specific for MHC class I this 
hypothesis could be further proven (Yokoyama, Kehn et al. 1990, Yokoyama, Ryan et al. 
1991, Colonna and Samaridis 1995, Wagtmann, Biassoni et al. 1995). Typically, NK cells are 
seen as a part of the innate immune system as their surface receptors trigger an inhibitory 
or activating signal, which determines the fate of the other cell based on cell-cell contact 
(Lanier 2013). It is worth mentioning that all NK cell receptors are germline-encoded and 
are fully functional without prior chromosomal rearrangement. 
 
The overall balance of activating and inhibitory signals on virally infected or cancer cells will 
determine the outcome of NK cell reaction. In humans, inhibitory signals are mediated 
through recognition of self-human leukocyte antigen (HLA) class I on all cells by killer 
immunomodulatory-like receptors (KIRs) or other non-KIR inhibitory receptors on NK 
cells. According to current knowledge, during differentiation and maturation NK cells 
acquire one or more inhibitory receptors (NKG2A and KIRs) stochastically. So far, three 
inhibitory HLA class I ligand groups have been found to be crucial for NK cell function: 
KIR2DL1 detects HLA-C2 group antigens; KIR2DL2/DL3 is specific for HLA-C1, and 
KIR3DL1 detects the HLA-Bw4 epitope (Litwin, Gumperz et al. 1994, Gumperz, Litwin et 
al. 1995, Wagtmann, Rajagopalan et al. 1995, Pittari, Vago et al. 2017). The non-KIR 
inhibitory receptors like the CD94/NKG2A heterodimer engage with HLA-E, while CD161 
recognizes lectin-like transcript 1 (Lanier, Chang et al. 1994, Braud, Allan et al. 1998, Lee, 
Llano et al. 1998, Aldemir, Prod'homme et al. 2005). The expression of at least one 
inhibitory signal gives NK cells the "license to kill" as there is a need for a regulatory 
mechanism that counteracts the activating signal. 
 
On the other hand, NK cells also express a broad variety of different activating receptors 
such as natural cytotoxicity receptors (NCRs) NKp46 (CD335), NKp44 (CD336) and 
NKp30 (CD337), which are very potent and almost exclusively expressed on NK cells 
(Sivori, Vitale et al. 1997, Pessino, Sivori et al. 1998, Vitale, Bottino et al. 1998, Pende, 
Parolini et al. 1999). NKp46 and NKp44 are known to recognize several viral hemagglutinins, 
while NKp30 binds to HLA-B-associated transcript 3 (BAT3), B7-H6 and BAG6 (Arnon, Lev 
et al. 2001, Mandelboim, Lieberman et al. 2001, Pogge von Strandmann, Simhadri et al. 2007, 
Brandt, Baratin et al. 2009, Rusakiewicz, Perier et al. 2017). It is very likely that not all ligands 
have been discovered yet. With the exception of one, members of another activating 
receptor group, called signaling lymphocytic activation molecule (SLAM), are all self-ligands 
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and triggered by self-engagement. The exceptional member of this family is 2B4 (CD244), 
which interacts with CD48 on other cells. The other two members are NTB-A (natural 
killer, T and B cell antigen) and CRACC (CD2-like receptor activating cytotoxic cells, 
CD319, CS1) which both engage with themselves (Cruz-Munoz, Dong et al. 2009). 
Belonging to the NKG2 receptor family, NKG2D (CD314) is specific for detection of several 
stress-induced ligands, including the MHC-related ligands MICA (MHC class 1 polypeptide-
related sequence A) and MICB as well as the human cytomegalovirus glycoprotein (UL16)-
binding proteins ULBP1-6 (Bauer, Groh et al. 1999, Cosman, Mullberg et al. 2001). Similar 
to its inhibitory counterpart CD94/NKG2A, the activating heterodimer CD94/NKG2C 
(CD159c) binds to HLA-E (Gumperz, Litwin et al. 1995). NK cells can get activated via low 
affinity immunoglobulin gamma Fc region receptor III (FcγRIII, CD16). Upon activation, NK 
cells form a synapse with the target cell and release the lytic proteins perforin and granzyme 
which consequently lead to lysis of the target cells (Perussia, Acuto et al. 1983, Titus, Perez 
et al. 1987, Garrido, Perez et al. 1990, Mandelboim, Malik et al. 1999). Additionally, the 
SLAM-related surface receptor 2B4 (CD244) detects CD48; while DNAM-1 (DNAX 
Accessory Molecule-1) recognizes the poliovirus receptor (PVR, CD155) and Nectin-2 
(CD112) (Bottino, Castriconi et al. 2003, Castriconi, Dondero et al. 2004, Fuchs, Cella et 
al. 2004, Tahara-Hanaoka, Shibuya et al. 2006, El-Sherbiny, Meade et al. 2007). 
 
Hematopoietic stem cells (HSC) give rise to NK cells and the NK cell maturation is divided 
into five stages (Eissens, Spanholtz et al. 2012, Freud, Yu et al. 2014). To determine the five 
stages, the following surface markers are checked: CD34, CD117, CD94, CD56, and CD16. 
CD34+CD117-CD94-CD56-CD16-identifies stage one. Stage two is defined through the 
acquisition of CD117 and their capability to respond to interleukin (IL)-15, which is an 
important feature for later NK cell development (Suzuki, Duncan et al. 1997, Carotta, Pang 
et al. 2011). Between stages two and three pre-NK cells lose their CD34 expression and 
start expressing CD56 to a small extent. Finally, mature NK cells are defined in two separate 
stages. Stage four is characterized as CD56brightCD94+CD16- cells while stage five NK cells 
express CD56dimCD94+/-CD16+. The major differences between stage four and stage five 
NK cells are that CD56dim (stage five) show significantly higher cytotoxic activity and contain 
much more perforin and granzyme while CD56bright (stage four) are more efficient producers 
of pro-inflammatory cytokines (Cooper, Fehniger et al. 2001, Jacobs, Hintzen et al. 2001, 
Poli, Michel et al. 2009). It has also been shown that CD56dim NK cells respond better to 
direct receptor ligand interaction and the CD56bright subset responds better to soluble 
factors (Long, Kim et al. 2013). The ratio between CD56bright and CD56dim is about 1:9 in 
peripheral blood respectively. Also, the pattern of surface receptor expression differs 
between the CD56bright and CD56dim populations. CD56dim express CD16 and inhibitory KIRs 
while CD56bright are negative for CD16a and KIRs but positive for NKG2A and the IL-2 
receptor α chain (IL-2R α /CD25) (Fehniger, Cooper et al. 2003, Ferlazzo, Thomas et al. 
2004). 
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1.2.1 Natural killer cell effector mechanisms 
 
The phenotype between the two mature NK cell subsets differ as described above, but 
more importantly their effector functions vary in regards to antibody-dependent cellular 
cytotoxicity (ADCC) and response to IL-2 stimulation. In the resting stage, CD56bright NK 
cells express less cytotoxic proteins, partially express CD16 and have CD94/NKG2A rather 
than KIRs as a sensor for self-tolerance. Upon stimulation with cytokines or via activating 
receptors, CD56bright are potent producers of cytokines (Wagner, Rosario et al. 2017). In 
contrast, CD56dim NK cells, which have KIR expression, are potent cytotoxic effector cells 
(Lanier, Le et al. 1986). This evidence suggests that CD56bright and CD56dim are distinct 
lymphocytes with unique tasks as innate immune cells and that all NK cells are not a 
homogenous population (Gonzaga, Matzinger et al. 2011). Although NK cells can kill 
malignant tumor cells or virus-infected cells without prior sensitization, they are also able 
to produce cytokines like TNF (tumor necrosis factor) and IFN-γ (interferon-γ)(Fauriat, 
Long et al. 2010).  
 
Moreover, NK cells have been reported to secrete several other factors, including 
immunoregulatory cytokines such as IL-5, IL-10, IL-13, the growth factor GM-CSF, and the 
chemokines MIP-1α, MIP-1β, IL-8, and RANTES (Cuturi, Anegon et al. 1989, Smyth, 
Zachariae et al. 1991, Warren, Kinnear et al. 1995, Bluman, Bartynski et al. 1996, Oliva, 
Kinter et al. 1998, Fehniger, Shah et al. 1999, Roda, Parihar et al. 2006). Secretion of these 
factors has a regulatory impact on the immune system and thus builds a bridge between the 
innate and the adaptive immune system.  
 
NK cells also share even more characteristics with the adaptive immune system. It has been 
shown that NK cells can be activated by dendritic cells (DC), be involved in autoimmune 
response and can recognize and respond to viral peptides (Arase, Mocarski et al. 2002, 
Ferlazzo and Munz 2004, Nelson, Martin et al. 2004, Fadda, Borhis et al. 2010). NK cells are 
also able to modulate DC functions. In-vitro assays have shown that NK cell can help in the 
DC maturation process through either killing immature DCs or direct stimulation of DCs 
(Ferlazzo, Semino et al. 2001). The fate of DCs is determined by the amount of MHC class 
I molecules on the DC surface and the expression of NK-activating receptors. Thus, mature 
DCs are spared from NK cell-mediated killing due to their high expression of MHC class I 
molecules (Ferlazzo, Tsang et al. 2002, Piccioli, Sbrana et al. 2002, Ferlazzo 2005). 
Furthermore, several groups have seen that after some viral infections or cancer, specific 
NK subpopulations stably expand and provide a long-lasting control over these diseases 
(Martin, Gao et al. 2002, Lopez-Botet, Angulo et al. 2004, Campillo, Martinez-Escribano et 
al. 2006, Martin, Qi et al. 2007, Alter, Rihn et al. 2009). All in all, NK cells do not only have 
innate but also adaptive features and can build up a memory-like NK cell pool.  
 
Although it has been known for a while that NK cells are essential for control of viral 
infections, and that deficiencies in NK cell numbers in humans is associated with increased 
susceptibility to herpes virus infections, no antigen-specific memory-like NK cells could be 
detected (Orange 2002). The first evidence of NK cells showing a memory function was 
found in a mouse model in 2004 where O'Leary et al. reported that a specific subset of liver-
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resident NK cells showed antigen-specific long-lived immunological recall responses to 
haptens (O'Leary, Goodarzi et al. 2006). Later in 2009 the same phenomenon was observed 
in murine cytomegalovirus (MCMV) infected mice (Sun, Beilke et al. 2009). The m157 
glycoprotein, which is expressed on MCMV infected cells, can induce a selective expansion 
and activation of NK cell subsets that are long lasting and show memory-like features 
(Dokun, Kim et al. 2001). Upon re-challenging with MCMV those MCMV-specific NK cells 
can respond more rapidly and effectively than naive NK cells (Sun, Beilke et al. 2009). Similar 
to MCMV, human CMV (HCMV) is also able to induce expansion of a specific subpopulation 
that is defined as CD94/NKG2C+CD57+ which is highly specific to HCMV, although the 
ligand for this has not yet been identified (Guma, Angulo et al. 2004, Lopez-Verges, Milush 
et al. 2011, Della Chiesa, Falco et al. 2013, Hendricks, Balfour et al. 2014, Muntasell, 
Pupuleku et al. 2016).  
 
Upon engagement with a target cell and in case the activating signal is more dominant than 
the inhibitory signal, polarization and exocytosis of granules towards the target cells are 
initiated. The released granules are filled with perforin and granzyme. The role of perforin 
is to create pores in the target cell membrane, while that of granzyme is to enter the cell 
through these pores to then induce caspase-mediated apoptosis (Bryceson, March et al. 
2006, Voskoboinik, Smyth et al. 2006). In addition to perforin and granzyme mediated 
apoptosis after degranulation, NK cells are also able to kill by receptor-ligand interaction. 
Tumor necrosis factor ligand superfamily member 6 (FasL) and TNF-related apoptosis-
inducing ligand (TRAIL) are known as death ligands on NK cells. Their corresponding 
receptors Fas and TRAILR found on tumor cells induce apoptosis in the target cells 
(Medvedev, Johnsen et al. 1997). The tumor microenvironment can downregulate activating 
ligands and can skew the NK cell phenotype due to secretion of cytokines to escape immune 
surveillance (Jinushi, Takehara et al. 2005, Konjevic, Mirjacic Martinovic et al. 2007). 
Therefore, it is critical for NK cells to have an alternative mechanism of targeting tumor 
cells in cases where the ligand is shed or activating receptors are downregulated (Lundqvist, 
Abrams et al. 2006). 
 
1.2.2 Natural killer cells in multiple myeloma 
 
As previously stated, the control of NK cell-mediated tolerance needs a delicate balance 
between activating and inhibiting signals that regulate the activity of NK cells in the steady 
state. When a tumor progresses, this equilibrium is usually out of balance due to the 
influence of tumor cells on the homeostasis of the immune system. Detection of MHC class 
I on the surface of tumor cells can inhibit NK cell killing, while the lack of MHC class I 
diminishes the inhibitory signal, which can lead to lysis of the tumor cell. 
 
Different tumors have found distinct ways to overcome NK cell-mediated killing. Some 
tumor cells are able to induce apoptosis in NK cells by engaging with NCRs. Engagement of 
those receptors leads to upregulation of FasL mRNA and consequently protein synthesis, 
which can interact with Fas at NK cell surface and induce suicide (Poggi, Massaro et al. 
2005). Costello et al. show that in acute myeloid leukemia (AML), NCRs on the cell surface 
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are significantly down-regulated (Costello, Sivori et al. 2002). Additionally, numerous other 
malignancies show a modulation of the immune system by the tumor to escape detection 
or killing (Zitvogel, Tesniere et al. 2006). Hepatocellular carcinoma, metastatic melanoma, 
chronic lymphocytic leukemia (CLL), and multiple myeloma regulate the NK cell population 
in a way that the detection of the tumor is defective (Jinushi, Takehara et al. 2005, Fauriat, 
Mallet et al. 2006, El-Sherbiny, Meade et al. 2007, Konjevic, Mirjacic Martinovic et al. 2007, 
Veuillen, Aurran-Schleinitz et al. 2012). This can happen through upregulation of MHC class 
I on the tumor cells or by modulation of the NK cell phenotype and function (Pierson and 
Miller 1996, Classen, Falk et al. 2003, Costello, Fauriat et al. 2004).  
 
Additionally, tumor cells can also escape immune surveillance by downregulation of 
activating ligands or through ligand shedding. MICA and MICB, which are the natural ligands 
for the activating receptor NKG2D, are overexpressed in malignant transformed cells, due 
to cellular stress (Pende, Rivera et al. 2002). However, to avoid NK immune surveillance, 
MM cells and other tumors can shed membrane-bound MIC (Jinushi, Takehara et al. 2005, 
Boissel, Rea et al. 2006, Jinushi, Vanneman et al. 2008, Kohga, Takehara et al. 2008). The 
presence of soluble MIC (sMIC) leads to internalization of surface NKG2D as well as NCRs 
which consequently impair NK cell effectiveness (Groh, Wu et al. 2002, Doubrovina, 
Doubrovin et al. 2003, Wu, Higgins et al. 2004). In line with these findings it is not surprising 
that the presence of sMIC is associated with poor cancer survival (Pittari, Vago et al. 2017). 
The same mechanism applies to the NCR NKp30 where circulating BAT3 can inhibit NK 
cell cytotoxicity and also leads to NKp30-specific hypo-responsiveness (Reiners, Topolar et 
al. 2013).  
 
Cancer cells are not only able to shed surface ligands to avoid detection. They also 
frequently upregulate non-classical MHC class I molecule HLA-G, which dampens NK cell 
response by activating the inhibitory receptors ILT-2 and KIR2DL4 (Rouas-Freiss, Moreau 
et al. 2005, Urosevic and Dummer 2008). Additionally, the upregulation of the non-classical 
HLA class 1 antigen HLA-E is related to a poor prognosis, and it could be shown that MM 
cells with increased HLA-E expression are less susceptible to killing by NKG2A+ NK cells 
(Bossard, Bezieau et al. 2012, Sarkar, van Gelder et al. 2015). Cell lines that were created 
from MM patients showed downregulated B7-H6 resulting in an NKp30-mediated 
impairment of NK cell functionality (Fiegler, Textor et al. 2013). Interestingly, early stage 
MM patients show low levels of HLA class I expression, while plasma cells from patients 
with advanced MM show high HLA class I expression which could potentially be a 
mechanism to avoid NK cell-mediated killing due to induction of inhibitory signaling 
pathways on NK cells (Carbone, Neri et al. 2005).  
 
Modulation of the BM and creation of an immunosuppressive milieu is not the only effect 
that the progression of MM has on the NK cell population. It has been found that in early 
stage and/or untreated MM, NK cell counts are similar or sometimes even elevated (Omede, 
Boccadoro et al. 1990, Osterborg, Nilsson et al. 1990, Famularo, D'Ambrosio et al. 1992). 
This would suggest that NK cell-mediated surveillance controls the disease, but it could also 
be understood as an effect of immunological stress due to poor disease management (Pittari, 
Vago et al. 2017). NK cells from MM patients also have an exhausted phenotype that includes 
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downregulation of several activating receptors and upregulation of programmed death 
receptor (PD)-1. The activating receptors that are affected by the downregulation are 2B4, 
NKG2D and also the NCRs, which are both decreased in circulating and in BM NK cells 
(Fauriat, Mallet et al. 2006, Costello, Boehrer et al. 2013). Compared to healthy donors or 
MM patients in remission, expression levels of DNAM-1 are also lower in patients with 
active MM, which consequently has an impact on late-stage tumor immune escape due to 
lack of interaction with PVR and nectin-2 that are most important for cancer cell elimination 
(El-Sherbiny, Meade et al. 2007, Guillerey, Ferrari de Andrade et al. 2015). Therefore, the 
phenotype and function of NK cells in active MM is skewed and hence the immune 
surveillance by NK cells is disturbed, which leads to immune escape of MM (Jurisic, Srdic et 
al. 2007).  
 
1.3 BONE MARROW MICROENVIRONMENT IN MULTIPLE MYELOMA 
 
MM develops in the BM, which is the primary site of hematopoiesis in adults. Hematopoietic 
stem cells give rise to several types of blood cells like immune cells, erythrocytes, platelets 
and others. Moreover, the microenvironment in the BM provides optimal conditions for 
maintenance, proliferation, and differentiation of various cell types and provides the primary 
home of plasma cells (Wilson and Trumpp 2006, Tangye 2011, Chu and Berek 2013). The 
BM microenvironment contains cellular compartments, extracellular matrix and also soluble 
factors like cytokines, chemokines and growth factors which are needed to form the BM 
niche (Romano, Conticello et al. 2014, Kawano, Moschetta et al. 2015). 
 
In the early stages of MM, it has been shown that the cells are strictly dependent on the BM 
and even in later stages the dependency on a tumor supporting environment is crucial for 
MM cell proliferation (Kuehl and Bergsagel 2002); additionally ex-vivo studies revealed that 
culturing MM cells is very challenging (Hughes 2011, Duru, Sutlu et al. 2015). Probably the 
most essential factor for MM cell growth in the BM is the cytokine IL-6 (Hirano and 
Kishimoto 1989, Suematsu, Hibi et al. 1990). Interestingly, the response to IL-6 stimulation 
is quite different in normal and malignant plasma cells. While IL-6 stimulates the production 
of Ig in normal plasma cells, it promotes proliferation and resistance to apoptosis in MM 
cells (Mitsiades, McMillin et al. 2007). Although MM cells can produce IL-6, the predominant 
source is other cell types like T cells, B cells and bone marrow stromal cells (BMSC) 
(Kishimoto, Hibi et al. 1992, Gunn, Conley et al. 2006). Together with the high levels of IL-
6, IL-10 is also increased in MM and acts as a growth factor for plasma cells (Bataille, Jourdan 
et al. 1989, Zhang, Klein et al. 1989, Kovacs 2010, Sharma, Khan et al. 2010, Zheng, Zhang 
et al. 2013). The effects of both IL-6 and IL-10 on the immune system impair NK cell activity 
and inhibit the production of IFN-γ and TNF, which are pro-inflammatory cytokines 
(Tsuruma, Yagihashi et al. 1999, Conti, Kempuraj et al. 2003, Cifaldi, Prencipe et al. 2015). 
The MM cells together with regulatory T cells (Treg) create an immunosuppressive milieu 
due to the production of high levels of transforming growth factor (TGF)-β, which is known 
to downregulate the expression of activating receptors. This affects not only NK cell 
cytotoxicity but also leads to impaired T cell response and defective antigen presentation 
by DCs (Urashima, Ogata et al. 1996, Cook and Campbell 1999, Castriconi, Cantoni et al. 
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2003, Lee, Lee et al. 2004, Pinzon-Charry, Maxwell et al. 2005, Beyer, Kochanek et al. 2006, 
El-Sherbiny, Meade et al. 2007). 
 
Cytokines modulate the immune response in the BM, but also other soluble factors are 
known to suppress NK cell functions. Prostaglandin E2 inhibits signal transduction from 
several activating receptors and Indoleamine 2,3-dioxygenase converts the essential amino 
acid l-tryptophan into l-kynurenine and thus inhibits immune effector cells by depletion of l-
tryptophan (Lu, Bataille et al. 1995, Mellor and Munn 1999, Munn, Shafizadeh et al. 1999, 
Martinet, Jean et al. 2010).  
 
One of the hallmarks of cancer is inflammation and it has been well described that an 
inflammatory microenvironment promotes tumor growth (Colotta, Allavena et al. 2009, 
Grivennikov, Greten et al. 2010). In solid tumors myeloid-derived suppressor cells (MDSC) 
and tumor-associated macrophages (TAM) play a pivotal role in dampening the body’s 
immune response and creating a tumor friendly milieu (Berardi, Ria et al. 2013). This has 
not been proven for hematological malignancies, but there is emerging evidence that the 
same cell types are involved (Berardi, Ria et al. 2013). MDSC levels are elevated in MM and 
they can directly contribute to reduced NK cell function through membrane bound tumor 
growth factor (TGF-β) and TIGIT (T cell immunoreceptor with Ig and ITIM domains)-
mediated inhibitory signaling towards the DNAM-1 signaling pathway (Li, Han et al. 2009, 
Van Valckenborgh, Schouppe et al. 2012, Zhuang, Zhang et al. 2012, Sarhan, Cichocki et al. 
2016).  
 
MM cells do not only change the BM niche into a milieu that accommodates their needs and 
promotes proliferation, but they also change the immune response of the body. Altogether, 
there is emerging evidence that the change in the immune system is driving MGUS to MM 
progression and it thus has an essential role in disease progression (Dhodapkar, Krasovsky 
et al. 2003, Perez-Andres, Almeida et al. 2005, Bernal, Garrido et al. 2009).  
 
1.4 HISTORY OF MULTIPLE MYELOMA TREATMENT 
 
Historically, MM was treated with different kinds of natural medicine e.g. rhubarb pills, 
orange peel or urethane (Solly 1844, Macintyre 1850, Longsworth, Shedlovsky et al. 1939, 
Alwall 1947, Alwall 1952). In 1958, Blokhin et al. reported for the first time on the treatment 
of MM with melphalan which showed some impact on lowering serum levels, although a 
survival benefit could not be observed (Blokhin, Larionov et al. 1958, Bergsagel, Sprague et 
al. 1962, Mass 1962, Hoogstraten, Sheehe et al. 1967). In 1969, Alexanian et al. introduced 
the combination of melphalan and prednisone (MP) which was the first effective therapy 
against MM and became the standard until the late 1990s (Alexanian, Haut et al. 1969).  
 
MM responds to classical cytotoxic, immunomodulatory and other targeted drugs and also 
to cell-based therapies like autologous and allogeneic stem cell transplantation (Gahrton 
2004). The overall survival (OS) of patients with newly diagnosed MM has increased from 
approximately three years during the years 1985–1998 to six to ten years today (Kyle, Gertz 
et al. 2003, Moreau, Attal et al. 2015). Due to the persistence of residual tumor cells, MM 
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is still considered to be an incurable disease and all patients eventually relapse. However, 
new and improved therapies or combinations have considerably improved survival rates and 
quality of life for many patients (Kaufmann, Urbauer et al. 2001, Alici, Bjorkstrand et al. 
2007).  
 
1.4.1 Immunomodulatory drugs 
 
The treatment possibilities have progressed dramatically with the introduction of the first 
novel agent, Thalidomide, which was the first immunomodulatory drug (IMiD) used in 
treating MM in 1999 (Singhal, Mehta et al. 1999). Initially, Thalidomide was developed in 
West Germany in the 1950s and sold as a sedative and a treatment modality of pregnancy-
related morning sickness and nausea. The drug was withdrawn from the market in the 
beginning of the 1960s due to its severe teratogenic side effect (Kyle, Gertz et al. 2003, 
Badros, Goloubeva et al. 2005). As the name IMiD implies, this drug type not only inhibits 
the proliferation of the malignant cells and hampers the interaction of tumor cells and their 
microenvironment, but also interact with the immune system by activation of T cells and 
NK cells (Quach, Ritchie et al. 2010). 
 
Although Thalidomide in combination with MP has shown an OS benefit of six months, 
researchers and clinicians have been searching for drugs with fewer side effects and higher 
potency (Fayers, Palumbo et al. 2011). In line with this, Lenalidomide (Len) was approved in 
2006 and consequently Pomalidomide (Pom) in 2012, which are now considered second 
generation IMiDs.  
 
1.4.2 IMiDs and mechanism of action 
 
The mechanisms of action for IMiDs are multifarious. A critical part of the immune 
modulation is the binding of Len to the protein cereblon (Ito, Ando et al. 2010). IMiDs target 
two ubiquitin ligase complexes directly, which consequently leads to the degradation of the 
transcription factors IKZF1 and IKZF3 (Ikaros and Aiolos, respectively) (Kronke, Udeshi et 
al. 2014). Followed by a cascade reaction, those missing transcription factors lead to down-
regulation of the transcription factors IRF4 and MYC which are essential for MM cell survival 
(Shaffer, Emre et al. 2008).  
 
The survival of MM cells is facilitated by an impairment of the immune system (Zou 2005). 
MM skews the immune system in a way that B and T cells are inhibited by myeloma-derived 
cytokines like TGF-β as well as inadequate antigen presentation, resistance to NK cell lysis, 
and defective T, B and NK cells (Brown, Pope et al. 2001, Smyth, Godfrey et al. 2001, 
Brimnes, Svane et al. 2006). Additionally, both humoral and cellular immunity are damaged. 
Thus, MM is associated with impaired B-cell differentiation and antibody responses, reduced 
T cell numbers, more specifically CD4+ T cells, abnormal T helper (Th)1/Th2 CD4+ T cell 
ratio, impaired cytotoxic T cell responses, dysfunction of NK and NKT cells, and defective 
DC function (Rawstron, Davies et al. 1998, Brown, Pope et al. 2001, Dhodapkar, Geller et 
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al. 2003, Maecker, Anderson et al. 2003, Ogawara, Handa et al. 2005, Jarahian, Watzl et al. 
2007). 
 
Interaction of Thalidomide or other IMiDs with the immune system breaks the myeloma 
cell "tolerance" by co-stimulation of T cells, interaction with Tregs and enhancement of NK 
and NKT cells (Quach, Ritchie et al. 2010). Both CD4+ and CD8+ T cells will be skewed 
towards enhanced production of Th1 type cytokines and show enhanced proliferation 
(Davies, Raje et al. 2001). In terms of co-stimulation and induction of proliferation, Len is 
more potent than Thalidomide (Corral and Kaplan 1999, Davies, Raje et al. 2001). Pom 
appears to induce co-stimulation even better than Len and shows similar Th1 type cytokine 
production (Schafer, Gandhi et al. 2003). The exact mechanisms and targets by which T cell 
proliferation and activation are induced by IMIDs are currently unknown. However, it has 
been shown that both Thalidomide and Pom enhance the activity of activator protein-1 (AP-
1), which is a key driver to IL-2 production (Schafer, Gandhi et al. 2003). The increased 
production of IL-2 promotes NK cell proliferation and activation and thus has a direct effect 
on the activity of the innate and adaptive immune system (Davies, Raje et al. 2001, Hayashi, 
Hideshima et al. 2005).  
 
The previously mentioned boosting of the innate immune system by IMiDs is mainly due to 
NK and NKT cell activation and is well documented (Davies, Raje et al. 2001, Hayashi, 
Hideshima et al. 2005). The increased production of IL-2 by activated T cells leads to a direct 
stimulation and increased function of NK cells. It has been shown by Davies et al. that Len, 
Thalidomide and Pom promote NK cell proliferation and enhanced death of MM cell lines 
and also primary patient cancer cells in-vitro (Davies, Raje et al. 2001). Interestingly, only 
Pom and Len can induce enhanced ADCC and natural cytotoxicity of NK cells in addition 
to their increase in proliferation (Hayashi, Hideshima et al. 2005, Tai, Li et al. 2005). It is 
also interesting to note that the in-vitro augmentation of ADCC on NK cells by IMiDs 
requires both antibody (Ab) binding to Fc-γ receptors on NK cells, as well as the presence 
of IL-2 (Hayashi, Hideshima et al. 2005, Tai, Li et al. 2005). So far, in-vitro studies have 
demonstrated that IMiDs stimulate T cell and NKT cell production of IL-2 and IFN-γ, which 
has a direct impact on NK cell-mediated cytotoxicity and proliferation. NK cells in turn 
produce cytokines like monocyte-recruiting chemotactic protein (MCP-1) and GM-CSF in 
response to Ab-coated target cells, which recruit DCs and T cells (Roda, Parihar et al. 2006). 
This results in further chemotactic attraction of tumor-specific T cells in the presence of 
IMiDs. A summary over the various effects of IMiDs on the immune system is shown in 
Figure 1. 
 
All in all, the development of IMiDs as a single agent or combination therapy together with 
autologous stem cell transplantation (ASCT) has drastically improved the treatment 
possibilities. Although for the majority of patients the standard treatment is still different 
chemotherapeutical agents that target and destroy the cancer cells. New combination 
therapies with proteasome inhibitors (PIs) and IMiDs lead to higher response rates 
compared to chemotherapy alone and thus to improved OS (Dimopoulos, Zervas et al. 
2001, Mitsiades, Hideshima et al. 2009, Ponisch, Andrea et al. 2012, Mina, Cerrato et al. 
2016). Particularly the combination with bisphosphonates leads to response rates of up to 
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80% in newly diagnosed patients and up to 75 % in patients with a relapsed disease (Garcia-
Sanz, Gonzalez-Fraile et al. 2002, Palumbo, Bertola et al. 2005). In addition to the 
conventional therapeutic approaches, the highest hopes for curing this disease rest on 
immunotherapy. Utilizing the body’s own immune system with monoclonal antibodies 
(mAbs), activated or genetically modified cells have the characteristics to target the tumor 
more precisely and direct while improving cytotoxicity with lower collateral damage to 
other cells and tissue of the patient. 
 
 
 
Figure I: Overview of the immunomodulatory outcomes of immunomodulatory drugs. 
BMSC: bone marrow stromal cells; APC: antigen-presenting cells; IL: interleukin; TGF: 
transforming growth factor; TNF: tumor necrosis factor; VEGF: vascular endothelia growth 
factor; ADCC: antibody-dependent cellular toxicity; MHC: major histocompatibility 
complex; TCR: T cell receptor; NF-κB: Nuclear factor kappa B; PI3k: phosphoinositide 3-
kinase; NFAT: nuclear factor of activated T cell; IFN: interferon; NK: natural killer. 
Adapted from (Quach, Ritchie et al. 2010) 
 
1.4.3 Proteasome inhibitors in multiple myeloma 
 
The ubiquitin-proteasome pathway (UPP) which is the major pathway for intracellular 
protein degradation can be defective in cancer cells. Thus, inhibiting this pathway would 
prevent malignant cells from proliferating (Voorhees, Dees et al. 2003, Crawford, Walker 
et al. 2011). Blocking the UPP with PIs is particularly useful in MM cells. Upon treatment 
with PIs, misfolded Ig accumulate in the endoplasmatic reticulum (ER) which then activates 
the proteasome function (Obeng, Carlson et al. 2006). This creates prolonged stress in the 
MM cells which consequently activates pathways that lead to cell cycle arrest and induction 
of apoptosis (McCullough, Martindale et al. 2001).  
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Currently, three different PIs are approved for the treatment of MM. The oldest one, 
Bortezomib (Bort), was approved in 2003 after it showed a good response rate in 
relapsed/refractory MM (RRMM) as a single agent treatment and also in combination with 
IMiDs or alkylating agents like Dexamethasone (Dex) (Chauhan, Catley et al. 2005, 
Richardson, Sonneveld et al. 2005, Richardson, Xie et al. 2009). The second one, Carfilzomib 
(Carf), was approved in the US in 2012 and in Europe in 2016. Its chemical moiety is different 
from Bort, and the binding effect is irreversible, which means that restoration of proteasome 
activity is only possible by new synthesis of the required subunits (Kuhn, Chen et al. 2007). 
Similar to Bort, Carf has shown to be effective as a single agent drug, but the most effective 
treatment is also as a combination therapy with Len as demonstrated in the ASPIRE study 
(Papadopoulos, Siegel et al. 2015, Stewart, Rajkumar et al. 2015). The third approved PI is 
Ixazomib which was approved in the US in 2015 and can be administered orally. The 
chemical moiety is similar to Bort and targets the same subunit of the proteasome with 
greater potential activity against MM cells (Chauhan, Tian et al. 2011). In addition to those 
three approved PIs, several more are currently being tested in numerous clinical trials which 
should provide a better clinical outcome and reduced toxicity for MM patients (Kubiczkova, 
Pour et al. 2014).  
 
1.5 IMMUNOTHERAPY IN MULTIPLE MYELOMA 
 
Immunotherapy is defined as a treatment that uses certain parts of a person’s immune 
system to fight diseases such as cancer by either stimulating the body’s own immune system 
or giving the immune system supporting components that are man-made and have direct 
influence on the disease.  
 
Immunotherapy has proven to be a highly active area in cancer therapeutics that is being 
explored in patients with myeloma. Strategies stretch from currently used treatments to 
experimental approaches that are investigated in various clinical trials. Those strategies 
include mAbs to target myeloma-associated antigens, checkpoint inhibitors to induce T-cell 
activation, engineered effector cells to target myeloma cells, and vaccine therapy to restore 
tumor-specific T cells within the immune effector repertoire (Boussi and Niesvizky 2017). 
 
The most common form of immunotherapy is allogeneic stem cell transplantation (allo-SCT) 
where the donor’s immune system is utilized to target the cancer cells. Allo-SCT has been 
shown to yield a durable response in MM patients when receiving grafts from HLA-matched 
sibling donors and is the standard treatment in eligible MM patients. (Gahrton, Tura et al. 
1991, Martino, Recchia et al. 2016). ASCT can be used as either single or double treatment, 
if necessary. The use of allo-SCT following ASCT or as a salvage therapy on relapse is 
currently not recommended outside clinical trials or very specific patient conditions 
(Martino, Recchia et al. 2016). Several studies that compared double ASCTs with ASCT 
followed by reduced-intensity conditioning allo-SCT have yielded mixed results without any 
consistent OS benefit for the patients (Garban, Attal et al. 2006, Bruno, Rotta et al. 2007, 
Bjorkstrand, Iacobelli et al. 2011, Martino, Recchia et al. 2016). But it is worth mentioning 
that those studies have been overshadowed by treatment-related morbidity and mortality 
and that some patients did benefit from allo-SCT treatment.  
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1.5.1 Monoclonal antibodies in the treatment of multiple myeloma 
Monoclonal antibodies are the newest approach in the treatment of hematological 
malignancies. The first monoclonal antibodies approved by the US Food and Drug 
Administration (FDA) were for the treatment of B cell non-Hodgkin lymphoma (NHL), and 
they revolutionized the treatment outcome. The introduction of rituximab, an anti-CD20 
mAb, has improved the OS compared to the standard treatment by 10-15% in all age groups 
and showed no high toxicity (Coiffier, Lepage et al. 2002, Sehn, Donaldson et al. 2005). This 
success story has encouraged researchers to develop mABs for the treatment of MM as 
well. So far, two mABs have obtained FDA and European Medicines Agency (EMA) approval 
for treatment of MM: Daratumumab and Elotuzumab (Table I).  
 
 
1.5.2 Targeting CD319 on multiple myeloma cells 
 
Elotuzumab (Elo) is a humanized mAb which is used in MM treatment. It specifically targets 
CS1 (also called SLAMF7,CD319 or CRACC), which is a surface marker and member of the 
signaling lymphocyte activation molecule-related receptor family (SLAMF) (Kumaresan, Lai 
et al. 2002). CS1 is highly expressed on plasma cells in patients suffering from MGUS or MM 
and keeps high expression levels regardless of previous lines of therapy. However, other 
cell types like NK or NKT cells, as well as some T cell subsets and activated monocytes also 
express CSI although expression levels are significantly lower. No expression of CS1 could 
be found in healthy tissue, which allows a targeted treatment with minimal side effects (Hsi, 
Steinle et al. 2008, Tai, Dillon et al. 2008). 
 
The primary mechanism of action of Elo is binding directly to CS1 on the MM cells and 
inducing NK cell-mediated ADCC which is summarized in Figure 2 (Varga, Maglio et al. 
2018) This mechanism of action has been proven in several in-vitro studies and it could also 
be shown that NK cells could induce ADCC in MM cells from patients resistant to previous 
IMiDs or PIs treatments (Tai, Dillon et al. 2008). Initially tested in RRMM patients during a 
phase I study, Elo indicated to be a well-tolerated drug with only modest activity as 
monotherapy (Zonder, Mohrbacher et al. 2012). In later studies, the combination with Len 
or Bort led to an overall response rate which was more impressive and additionally 
Table 1: Daratumumab and Elotuzumab: targets, mechanisms of action and approved indications. 
Name Target 
Mechanism of 
action 
Completed 
Studies (Phase) 
Ongoing studies 
(Phase) 
Indication 
Elotuzumab 
CS1/SLAMF
7/CRACC 
ADCC, direct 
activation of NK cells 
RRMM (1/II/III) 
Newly diagnosed 
(III) SMM (II) 
Combination with Len-Dex 
(1-3 prior tx) 
Daratumumab CD38 
ADCC, ADCP, CDC, 
apoptosis via cross-
linking, depletion of 
Tregs 
RRMM (1/II/III) 
Newly diagnosed 
(III) SMM (II) 
Combination with Len-Dex 
or Bort-Dex (> 1 prior tx); 
monotherapy after at least 
3 prior tx 
ADCC, antibody-dependent cell-mediated cytotoxicity; ADCP, antibody-dependent cellular phagocytosis; Bort, bortezomib; CDC, 
complement- dependent cytotoxicity; Dex, dexamethasone; Len, lenalidomide; RRMM, relapsed/refractory multiple myeloma; SMM, 
smoldering multiple myeloma; tx, treatment.  
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increased the median time to progression (Jakubowiak, Benson et al. 2012, Lonial, Vij et al. 
2012).  
 
Later during a phase III study, Lonial et al. compared the combination of Elo with Len and 
Dex (ELd) against Len and Dex (Ld) alone. Progression-free survival (PFS) in the ELd group 
was significantly higher compared to the Ld group. Also, treatment-related side effects were 
lower in ELd treated patients. Interestingly, the infection rates were comparable except for 
the infection rate of herpes zoster, which was higher in the Elo group (Lonial, Dimopoulos 
et al. 2015). Overall it could be shown that the addition of Elo to Len and Dex led to a 
reduced risk of disease progression by 30%. Based on this study the FDA approved the use 
of Elo as a treatment option for patients with MM who had received one to three prior 
therapies (Varga, Maglio et al. 2018).  
 
 
Figure 2: Mechanism of action for Elotuzumab. CD: cluster of differentiation; SLAMF7: 
signaling lymphocytic activation molecule family member 7 (CS1, CD319); NK: natural killer. 
Adapted from (Varga, Maglio et al. 2018) 
 
1.5.3 Targeting CD38 on multiple myeloma cells 
 
CD38 is a 45 kDa type II transmembrane glycoprotein, which is highly and uniformly 
expressed on myeloma cells and plays a role in receptor-mediated signaling events for cell 
adhesion (Lin, Owens et al. 2004, Santonocito, Consoli et al. 2004, Deaglio, Vaisitti et al. 
2007); additionally, CD38 also plays a pivotal role in the intracellular mobilization of calcium 
NK cell
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Modified from: Varga, C et al. “Current use of monoclonal antibodies in the 
treatment of multiple myeloma” Br J Haematol, (2008) 181: 447-59. 2018
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(Deshpande, White et al. 2005). CD38 is expressed at low levels on normal lymphoid and 
myeloid cells but shows very high expression on malignant plasma cells in all stages of MM, 
making CD38 a valuable target for antibody therapy (Lin, Owens et al. 2004, Malavasi, 
Deaglio et al. 2008, Malavasi 2011). Although several anti-CD38 antibodies have been 
investigated, only Daratumumab (Dara), which has a fully humanized IgG1-κ isotype, 
received FDA-approval. Three other antibodies, Isatuximab, MOR202 and TAK-079 are 
currently tested in phase III and phase 1/II studies, respectively (Martin, Hsu et al. 2014, 
Martin, Mannis et al. 2016, Richter, Martin et al. 2016, van de Donk, Richardson et al. 2018). 
Notably, Isatuximab received orphan drug status in the beginning of 2019 when a phase III 
clinical trial met its primary endpoint of improved PFS in combination with Pom plus Dex 
compared to Pom plus Dex alone in RRMM.  
 
Dara specifically targets a unique epitope on CD38 and can destroy MM cells through 
multiple direct and indirect mechanisms (van de Donk, Moreau et al. 2016, Varga, Maglio et 
al. 2018). Coating of the target MM cells by Dara leads to detection and activation of effector 
cells that will kill the MM cells via ADCC through the release of cytotoxic granules or 
binding of cell death-inducing molecules like FasL (de Weers, Tai et al. 2011). Another 
mechanism of action is via complement dependent cytotoxicity (CDC), which starts by 
binding of the antibody and activation of the complement cascade, leading ultimately to cell 
lysis and death due to the interaction of the complement system with the cell membrane 
(de Weers, Tai et al. 2011). The third indirect killing mechanism is antibody-dependent 
cellular phagocytosis (ADCP), which is mediated by macrophages (Overdijk, Verploegen et 
al. 2015). Recently, it was also shown that Dara has a direct effect on the numbers of Tregs, 
which express high levels of CD38 and can therefore be a depleted due to Dara-mediated 
ADCC (Krejcik, Casneuf et al. 2016). An overview of the different effects of Dara is shown 
in Figure 3. 
 
Lenalidomide can be a potent inducer of NK cell activity and proliferation and it was 
previously shown that Len in combination with an anti-CD20 mAb, Rituximab, increases the 
ADCC effect in chronic lymphocytic leukemia (CLL) (Byrd, Peterson et al. 2005, Friedberg 
2008). This discovery led to the assumption that the combination of Dara with Len could 
also show synergistic effects. These were explored by Veer et al. in pre-clinical studies which 
demonstrated promising first results (van der Veer, de Weers et al. 2011). The POLLUX 
study later confirmed that combining Dara with Len induces a deep response in RRMM 
patients that lasted for over two years with a very favorable safety profile (Dimopoulos, 
Oriol et al. 2016, Moreau, Oriol et al. 2017, Plesner, Arkenau et al. 2017, Dimopoulos, San-
Miguel et al. 2018).  
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Figure 3: Mechanism of action for Daratumumab. CD: cluster of differentiation; C1q: 
complement component 1q; FasL: Tumor necrosis factor ligand superfamily member 6; NK: 
natural killer. 
Adapted from (Varga, Maglio et al. 2018) 
 
1.5.4 Co-inhibitory molecules 
 
The costimulatory pathway that is controlled by PD1/PD-ligand (PD-LI) helps maintain T 
cell homeostasis and also protects against autoimmunity. While PD1 is expressed on the 
surface of T cells, B cells and NK cells the corresponding ligands PD-L1 and PD-L2 are 
primarily expressed on DCs and macrophages (Keir, Butte et al. 2008). Upon binding of PD-
L1, T cells secrete less Th1-cytokines, proliferate less, and show lower T cell-mediated 
killing (Rosenblatt and Avigan 2017). MM cells, as many other cancer cells, abuse this system 
and create an immunosuppressive milieu by upregulating PD-L1 expression (Liu, Hamrouni 
et al. 2007, Gajewski, Schreiber et al. 2013, Tamura, Ishibashi et al. 2013). PD1 is also 
upregulated on T cells from MM patients; thus targeting PD1/PD-L1 by immune checkpoint 
inhibitors is a logical consequence. Although checkpoint inhibition showed remarkable 
therapeutic success in some solid malignancies, this effect could not yet be confirmed in MM 
treatment (Gay, D'Agostino et al. 2017, Jelinek, Mihalyova et al. 2017). PD1 blockade with 
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1b study, since no objective response could be observed in 67% of the patients (Lesokhin, 
Ansell et al. 2016). Another PD1 blocking mAb Pembrolizumab in combination with Len or 
Pom plus Dex showed a very good overall response rate and durable improvement in 
patients which are refractory to both IMiDs and PIs, although increased autoimmune 
disorders were observed (San Miguel, Mateos et al. 2015, Badros, Hyjek et al. 2017). Two 
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increased risk for death was observed with Pembrolizumab therapy. Later in 2017, the FDA 
also stopped three trials exploring Nivolumab-based treatment, which could be restarted 
after amendments. 
 
1.5.5 Adoptive T cell therapy 
 
Adoptive T cell therapy is a type of immunotherapy where isolated and/or expanded T cells 
are given to a patient to fight a disease. The expansion and activation of bone-marrow 
infiltrating lymphocytes (MILs) demonstrate enhanced antitumor specificity, effectively 
targeting plasma cells and their clonogenic precursors. In a phase 1 trial MILs were used to 
treat RRMM patients in combination with ASCT and the patients showed increased PFS by 
thirteen months but no increased OS (Noonan, Huff et al. 2015).  
 
One of the most promising new approaches is the use of chimeric antigen receptors (CAR) 
to modify T cells. The CARs consist of a variable antibody chain that specifically targets a 
surface molecule in their native conformation. In contrast to a T cell receptor (TCR), the 
CAR binds the target in an MHC-independent fashion. Initially, the first generations of CARs 
were engineered from a single-chain variable fragment from an antibody combined with an 
intracellular CD3z signaling domain. This construct showed poor clinical activity and 
persistence was very modest. To increase the effect of the CAR signaling domains, co-
stimulatory molecules such as CD28, CD137 (4-1BB) or CD134 (OX40) have been added 
to the construct. These modifications provided additional effector functions such as cytokine 
production or proliferation. The combination of two of those co-stimulatory domains built 
the basis for the third-generation of CARs; the typical combinations are CD28 plus 4-1BB 
or CD28 plus OX40 (Maus, Grupp et al. 2014).The effect of CAR T cells on CD19 
expressing and other B cell malignant tumor cells led to the development of CAR T cells 
for other targets (Maude, Frey et al. 2014, Kochenderfer, Dudley et al. 2015). 
 
Typical targets for MM cells are B or plasma cell-related surface receptors like B cell 
maturation antigen (BCMA), CS1, CD38, CD138. Both CS1 and CD38 are currently used 
for immunotherapy utilizing mAb in combination with IMiDs or PIs. BCMA, which is a 
protein that regulates B cell maturation and differentiation into plasma cells, is currently one 
of the main targets because of its almost unique expression on plasmablasts and plasma cells 
(Tai, Li et al. 2006, Jung, Lee et al. 2017). In an early phase, dose-escalating trial patients 
received CAR-BCMA T cells and the MM specific response was promising; the four given 
doses were 0.3 x106, 1x106 CAR, 3 x106 and 9 x106 CAR T cells/kg body weight, respectively. 
Overall, out of the twelve treated patients, six patients showed stable disease (SD), one 
achieved partial response (PR), two had very good partial responses (VGPR), and one 
showed complete response (CR), which demonstrated the potent capacity of CAR-BCMA 
T cells in MM patients (Ali, Shi et al. 2016). Other phase 1 and 1/II trials of CART-BCMA in 
MM are ongoing (NCT03093168, NCT03070327, NCT02954445).  
 
Although the results are promising, problems such as "on-target, off-tumor" toxicity and 
cytokine release syndrome (CRS) due to the CAR T cell infusion still exist (Dai, Wang et al. 
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2016). To overcome these problems, several approaches are possible. One is extensive 
screening of different CAR constructs on their on-tumor/off-tumor cytotoxicity. It has been 
shown that low affinity constructs can still mediate effective lysis of target cells as well as 
provide optimal proliferation and cytokine production (Drent, Themeli et al. 2017). Another 
approach is blocking the effects from IL-6, which play an important role in CRS, with an anti-
IL6 receptor antibody for better management of CRS upon manifestation (Fitzgerald, Weiss 
et al. 2017). 
 
1.5.6 Natural killer cell-based therapies 
 
The progression of MM is associated with abnormal NK cell counts with a defective 
phenotype and decreased cytotoxic functionality. However, it has also been shown by 
others and us that ex-vivo expansion and long-term activation with addition of IL-2 and anti-
CD3 mAb (OKT3) of autologous NK cells shows increased surface expression of activating 
receptors. Additionally, we also showed an elevated cytotoxicity against K562 target cells 
and autologous MM cells (Carlens, Gilljam et al. 2001, Alici, Sutlu et al. 2008) Although the 
exact role of OKT3 in this setting is unclear, it has been suggested that T cell activation 
leads to increased NK cell growth (Granzin, Wagner et al. 2017). Expanded donor derived 
NK cells from peripheral blood mononuclear cells (PBMCs) were used in a phase I clinical 
trial to treat five cancer patients. Infusion of the cells alone or in combination with 
subcutaneous IL-2 administration was save and no signs of acute graft versus host disease 
(GvHD) could be observed (Barkholt, Alici et al. 2009).  
 
Several different expansion methods are currently used and tested which differ in start 
material (total PBMCs, CD3 depleted PBMCs, CD56 enriched NK cells, etc.), medium used, 
expansion system and many more factors. In general, it is possible to distinguish NK cell 
expansion in two groups: feeder-free and with addition of feeder cells. The use of feeder 
cells for large scale expansion has several advantages as they provide additional stimulation 
for activation and proliferation. Several sources of feeder cells can be used. These include 
irradiated cell lines which can be engineered to either express membrane bound cytokines 
or costimulatory receptors on their surface, as well as irradiated autologous and allogeneic 
PBMCs (Fujisaki, Kakuda et al. 2009, Lundqvist, Berg et al. 2011, Granzin, Soltenborn et al. 
2015). However, contamination of residual feeder cells in the final product is a major 
concern for clinical applications and needs to be strictly controlled (Geraghty, Capes-Davis 
et al. 2014).  
 
Especially the use of K562 cells that are transfected with membrane-bound (mb) IL-15 or 
IL-21 together with CD137L (41BBL) show a robust ex-vivo expansion and propagation of 
highly activated cytotoxic NK cells (Denman, Senyukov et al. 2012, Wang, Lee et al. 2013). 
Transfer of such expanded and activated NK cells into a murine MM model show persistence 
of NK cells up to four weeks together with inhibited MM growth (Garg, Szmania et al. 2012). 
Following this success, the same group tested those cells in seven heavily pretreated patients 
with high-risk relapsing myeloma. The cells were administered either fresh or cryopreserved 
and interestingly, in-vivo expansion could only be observed in the five patients that received 
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fresh cells. No serious adverse events related to treatment was observed. However, just 
two out of seven patients showed responses, one showed partial response and in the other 
the time of disease progression was decreased (Szmania, Lapteva et al. 2015).  
 
In 2016, a phase I clinical trial (NCT02481934) was performed, where the combination of 
activated and expanded NK cells together with anti-myeloma drugs was tested in RRMM 
patients (Leivas, Perez-Martinez et al. 2016). NK cells were expanded for three weeks with 
K562-mbIL-15-41BBL feeder cells and then administered together with the pharmacological 
treatment. No major toxicities were reported, four out of five patients showed stabilization 
of the disease and two patients showed a 50% reduction in BM infiltration together with a 
response that lasted longer than one year. Infused cells are shown to have a highly cytotoxic 
phenotype with a high cytotoxicity in-vitro. Taken together, the ex-vivo expansion of 
autologous NK cells is feasible and these cells have an anti-tumor effect and multiple 
infusions are well tolerated in patients with relapsed or refractory myeloma. 
 
The combination of an artificial and engineered receptor like CAR with highly cytotoxic T 
cells showed very promising results in several hematological malignancies (Haji-Fatahaliha, 
Hosseini et al. 2016). However, treatment with CAR T cells raises concerns based on their 
side effects in specific prolonged aplasia of the healthy parts of the target tumor, "off-tumor, 
on-target toxicity" and cytokine release syndrome together with a possible GvHD for 
allogeneic T cell products (Casucci, Nicolis di Robilant et al. 2013, Casucci, Hawkins et al. 
2015). 
 
To overcome these problems, utilizing NK cells with CARs could lead to similar functional 
outcomes without severe side effects. Innate immune cells recognize tumor cells based on 
pre-defined patterns and have previously been used in allogeneic and autologous settings 
without extreme side effects (Veluchamy, Kok et al. 2017). Additionally, the lifespan of 
mature NK cells in an adaptive setting is limited to a few days up to a few weeks and they 
do not induce GvHD in the recipient (Brehm, Huenecke et al. 2014, Glienke, Esser et al. 
2015). One of the most significant limitations so far is the lack of persistence of NK cells in 
the allogeneic setting unless treatment is given to suppress rejection of the cells. 
Nevertheless, it has been shown in several studies that adoptive NK cell treatment has 
various advantages like the absence of life-threatening GvHD and major treatment-related 
toxicities (Miller, Soignier et al. 2005, Iliopoulou, Kountourakis et al. 2010, Rubnitz, Inaba et 
al. 2010, Bachanova, Cooley et al. 2014).  
 
1.5.7 Natural killer cell lines in cancer therapy 
 
The only NK cell line currently in use in the clinic is the NK cell line NK-92 that was isolated 
in 1992 from a 50-year-old male non-Hodgkin’s lymphoma patient (Gong, Maki et al. 1994). 
NK-92 cells are known to be highly cytotoxic against target cells like K562 or primary tumor 
targets (Klingemann, Wong et al. 1996, Tonn, Becker et al. 2001). They express most of the 
activating NK cell markers but lack CD16 and the majority of the KIRs (only KIR2DL4 is 
expressed at low levels) and thus have an advantage over allogeneic NK cells as no MHC-
class 1 restrictions apply (Maki, Klingemann et al. 2001). It is possible to grow NK-92 
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continuously in a feeder-free setting with the addition of IL-2 under current good 
manufacturing practices (CGMP) conditions to desired cell numbers for any possible 
treatment approach, which make them advantageous for an "off-the-shelf" immunotherapy 
product. Several clinical trials are currently exploring the possibility of using NK-92 for 
adoptive NK cell-based cancer immunotherapy (Suck, Odendahl et al. 2016).  
 
When used for clinical trials, NK-92 are thawed from a master cell bank that has been tested 
extensively for possible contaminations with human pathogens like hepatitis C, human 
immunodeficiency virus, herpes simplex virus 1 and II, cytomegalovirus as well as traces of 
bacteria, fungi or mycoplasma (Tonn, Becker et al. 2001). The first study in which NK-92 
cells were administered to patients already took place in 2001. In that study, NK-92 cells 
were irradiated prior to administration to 15 patients which suffered from high tumor load 
and had no other treatment options. Due to the bad shape the patients were in and the fact 
that all patients were immunocompromised, no efficacy could be evaluated. However, none 
of the patients suffered from severe side effects upon treatment with NK-92 independently 
of the infused dose (n = seven were given 1 × 109 cells/m2 body surface, n = six were given 
3 × 109 cells/m2 body surface, and two patients received the maximum dose of 1 × 1010 
cells/m2 body surface). Another trial reported in 2008 that NK-92 cells in metastatic renal 
cell carcinoma and malignant melanoma showed very low infusion-related toxicities with 
some anti-tumor response despite the bad conditions of the patients (Arai, Meagher et al. 
2008).  
 
Recently, it was proven feasible to modify NK-92 cells with a CAR construct targeting either 
CS1 or CD138. Neither surface receptor of the modified cells, nor the specific lysis of 
human malignant plasma cells ex-vivo and in a xenograft mouse model were changed after 
this modification (Chu, Deng et al. 2014, Jiang, Zhang et al. 2014). Whether one should use 
a cell line or primary NK cells as source for CAR-modified NK cells to get an optimal 
product is yet in discussion (Tonn, Schwabe et al. 2013). Several clinical trials are currently 
run in Germany, Canada, China and the United States, which use NK cell lines to treat 
several hematological and solid tumors (Nowakowska, Romanski et al. 2018, Tang, Yang et 
al. 2018, Tomalka, Resto-Garay et al. 2018, Zhang, Zhang et al. 2018).  
 
One of the arguments for using freshly isolated NK cells from peripheral blood is that they 
represent the most physiological source, although long-term cultivation and activation 
changes the receptor profile and could affect the functional competence of the cells. 
Another critical point is the possibility to achieve sufficient cell numbers for multiple 
infusions at high doses, especially for NK cells from immunocompromised patients. On the 
other hand, there is the immortalized cell line NK-92, a possible "off-the-shelf" product, 
with an inherent anti-tumor activity that can easily be modified genetically and banked. 
However, irradiation prior to infusion has an adverse effect on the in-vivo persistence of 
those cells and always carries a risk of not having a complete irradiation process (Tonn, 
Schwabe et al. 2013, Suck, Odendahl et al. 2016). Transduction of NK-92 cells with a CAR 
construct targeting CD138 led to enhanced cytotoxicity against CD138+ expressing cell lines 
and primary MM cells compared to the unmodified NK-92 cells. Interestingly, irradiation of 
those cells with 10Gy, which is necessary to block proliferation, did not weaken the 
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cytotoxic response of the modified NK-92 cells (Jiang, Zhang et al. 2014). In 2016 a group, 
from Ohio showed that MM cancer stem-like cells express very high CS1 levels and would 
thus be an optimal target for potential CS1-CAR NK cells. Additionally, they observed that 
Dara triggered IFN-γ production in NK cells is both CD38 and CD16 dependent, which 
could be confirmed for both primary NK and CD16+ NK-92 cells (Zhang, Chen et al. 2016). 
The combinatory targeting of CS1 together with CD38 through Dara could potentially have 
additive or synergistic effects to eradicate MM cells. This effect could be enhanced by the 
use of NK cells that are CD38-, as this would prevent Dara-mediated fratricide. Long term 
effects and first clinical results are not published yet.  
An overview of the different NK cell-based immunotherapy options is summarized in 
Figure 4.  
 
 
Figure 4: Overview of NK cell-related cancer immunotherapy options. CAR: chimeric 
antigen receptor; IL: interleukin; KIR: Killer cell immunoglobulin-like receptor; MICA: MHC 
class I polypeptide-related sequence A; NKG2A/D: natural killer group 2A/D; PD-1: 
programmed death-1; TIGIT: T cell immunoreceptor with Ig and ITIM domains; CD: cluster 
of differentiation; ADCC: antibody-dependent cellular cytotoxicity; mAb: monoclonal 
antibody; NK: natural killer. 
Adapted from (Lorenzo-Herrero, Lopez-Soto et al. 2018) 
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2 GENERAL AIMS OF THIS THESIS 
 
The first part of this thesis evolves around monoclonal antibody treatment in MM and its 
impact on the immune system of the patient. Being the first monoclonal antibody approved 
for MM treatment, Dara gives new hope for relapsed and refractory MM patients.  
 
In study 1 we aimed to understand how treatment with Dara would affect NK and T cells 
in those patients, and also looked into in-vitro toxicity as well as a possibility to treat patients 
with Dara consecutively.  
 
Following the findings in study I on the impact of NK cells in patients treated with Dara, we 
could then observe in study II that viral reactivations in patients treated with Dara were 
elevated despite antiviral prophylaxis. In study II we also compared clinical factors with 
immunological factors from flow cytometry-based phenotyping in order to see how the 
immune status of the patients changed with the administration of Dara. A lack of immune 
cells, especially NK cells, after Dara treatment, gives evidence that complementing adoptive 
cell therapy could have a positive impact on the disease progression in those patients.  
  
In study III we assessed the possibility to grow the clinically relevant NK cell line NK-92 
under serum-free conditions. It is known that serum has a big impact on expansion rates 
and phenotype, is also non-defined and has enormous batch to batch variations, which has 
a negative impact for clinical application. Creating a relatively cheap, reliable, xenofree 
culture system for NK-92 cells which retains their antitumor cytotoxicity would make an 
excellent “off-the-shelf” product for adoptive immunotherapy. This could potentially be 
complemented with other treatments such as monoclonal antibody therapy to achieve a 
synergistic effect. 
 
 

  25 
3 RESULTS & DISCUSSION 
 
3.1 STUDY I 
 
Re-challenging with anti-CD38 monotherapy in triple-refractory multiple 
myeloma patients is a feasible and safe approach 
 
 
Background 
 
MM is a chronic disease for which there is no curative treatment. Known prognostic 
parameters that have a significant impact on OS are the treatment regimen, the patient’s 
age, b2-microglobulin level and chromosomal aberrations (Harousseau, Avet-Loiseau et al. 
2009, Biran, Jagannath et al. 2013, Iriuchishima, Saitoh et al. 2014, Blimark, Turesson et al. 
2018). The type of clinical response (CR or PR) has also been shown to affect OS 
(Harousseau, Avet-Loiseau et al. 2009). During the last decades there have been 
considerable advances in the treatment outcome of MM. 
 
At the moment, the only treatment able to cure MM is allogeneic stem cell transplantation 
for eligible patients under 70. Conventional therapy includes alkylating agents in combination 
with IMiDs and PIs. Nevertheless, OS is still just 13 months and event-free survival is at 5 
months for patients that are double refractory to PIs and IMiDs (Weinhold, Ashby et al. 
2016). 
 
Dara, a monoclonal antibody targeting the CD38 epitope, which is highly expressed on 
malignant plasma cells, was approved for MM treatment by the U.S. FDA in 2015 and by the 
EMA in 2016 (Igarashi, Wynberg et al. 2004, Santonocito, Consoli et al. 2004, Lokhorst, 
Plesner et al. 2015). In RRMM, Dara is well tolerated and has demonstrated encouraging 
efficacy in MM patients (Plesner, Lokhorst et al. 2012). Together with Elo, Dara is the only 
monoclonal antibody for MM treatment with clinical approval; both can be used either as 
monotherapy or in combination treatment. 
 
 
Aim of the study 
 
In this study we investigated the feasibility of re-challenging two patients with Dara after 
they had progressed on this drug. We additionally monitored the immune status of those 
patients over the period of re-challenging to see the impact of the drug on the involved 
immune cells. Furthermore, we investigated the in-vitro toxicity of Dara on MM cells.  
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Results 
 
We treated two patients suffering from triple refractory (IMiDs, PI and Cytostatics) MM 
with Dara as their last treatment option. Both patients had been treated with Dara before 
and had shown a good response before they consequently relapsed. Since both were eligible 
for a second round of Dara treatment, we initiated re-treatment with Dara to which both 
responded. Decreased M component levels could be observed for >7 months.  
 
In order to see if this in-vivo effect could also be reproduced in-vitro and to understand the 
dose necessary for that, we incubated bone marrow cells before re-treatment with different 
doses of Dara. In the conditions where no Dara was added, we could observe a robust 
CD38 expression that was gradually decreased in a dose-dependent manner of Dara. 
Staining the samples with AnnexinV, which is an indicator for apoptosis, we could observe 
a direct dose-dependent effect of Dara on the MM cells and even a further increase of 
apoptosis when co-incubated with over-night IL-2 activated PBMCs, which underlines the 
ability of NK cells to kill the opsonized MM cells via ADCC.  
 
We also assessed the phenotype of NK and T cells in the PBMCs and could see an immediate 
drop of NK cell counts after administration of Dara. Levels dropped within one week from 
9% NK cells to around 2% in one of the patients and stayed that low during the whole 
treatment period. Furthermore, KIR phenotyping of circulating NK cells revealed a 
fluctuating KIR expression profile. CD57+ NK cells transiently decreased during treatment 
and increased at each treatment interruption, which suggests a decrease in the circulating 
mature NK cell population during treatment. We could also observe this fluctuation in 
circulating CD8+ T cells in patient one, where they completely disappeared after 
administration and reappeared during treatment interruptions. In addition, we also observed 
that during treatment interruption the number of anti-inflammatory myelomonocytes 
decreased drastically.  
 
 
Significance 
 
In this study, we could confirm that re-challenging triple refractory MM patients with Dara 
is possible and may offer new therapeutic treatment options as well as a possible synergy 
with adoptive NK cell treatment to maintain high levels of circulating NK cells.  
 
MM patients that are refractory to IMiDs, PIs and cytostatic drugs and are not eligible for 
autologous stem cell transplantation because of their health status, age or lack of a suitable 
donor don’t have any other treatment option left except the treatment with monoclonal 
antibodies like Dara or Elo. Dara, in general, is well tolerated and shows great single-agent 
activity, which leads to a positive response rate of about 36 % of all patients (Lokhorst, 
Laubach et al. 2014).  
 
The key factor for a successful response to Dara treatment is high levels of CD38 surface 
expression on the MM cells. Nijhof et al. recently confirmed in a meta-analysis of two large 
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clinical trials that patients who achieved at least PR had a higher baseline CD38 expression 
compared to patients who did not achieve PR (Nijhof, Casneuf et al. 2016). However, the 
range of CD38 expression levels widely overlaps between responders and non-responders, 
thus a selection just by CD38 is not suitable.  
 
As shown in this study, exposing Dara to MM cells in-vitro causes downregulation of CD38. 
This has also been confirmed by Nijhof et al. for several patients and various MM cell lines. 
MM cells were obtained before infusion, during treatment as well as at the progressive 
disease stage and CD38 levels were assessed respectively. Even after the first infusion, the 
surface expression of CD38 in the remaining MM cells was reduced by ~90%, as were the 
MM cell counts (Nijhof, Casneuf et al. 2016, Krejcik, Frerichs et al. 2017). The reduction of 
CD38 expression is a transient effect and is reversed after discontinuation of treatment 
with Dara (Nijhof, Casneuf et al. 2016). Several different mechanisms can lead to this 
reduction of CD38. After the direct response of the patient to Dara and the following 
elimination of MM cells with CD38high surface expression, only CD38low expressing cells 
remain. Also, internalization might also contribute to the loss of CD38. In addition, 
Horenstein et al. have published that CD38 molecules are able to cluster together and be 
released as tumor-derived microvesicles (Horenstein, Chillemi et al. 2015).  
 
In this study, we showed for the first time that following initial Dara treatment at relapse, 
MM cells retained high levels of CD38 expression, which was later confirmed by others 
(Nijhof, Casneuf et al. 2016). Additionally, we could achieve PR over 6 months for patient I 
and >8 months for patient 2. These findings lead us to believe that retreatment with Dara 
may be a feasible approach independent of cytogenetic abnormalities.  
  
One of the critical factors for re-treatment is the pool size of the effector cells exerting 
ADCC. NK cell-mediated killing of MM cells is an important aspect which determines the 
outcome of the response. It was shown that Dara-mediated ADCC is superior in patients 
with high NK cell to MM cell ratio, in comparison to a low NK cell to MM cell ratio; a similar 
effect could be observed for the frequency of activated circulating NK cells (Nijhof, Groen 
et al. 2015).  
 
As shown in this study and by others, the administration of Dara will almost immediately 
lead to a depletion of NK cells. The underlying mechanisms could be the relatively high 
expression of CD38 on NK cells which could result in NK cell fratricide via ADCC. 
Interestingly, it was published by Wang et al. recently, that after Dara administration NK 
cells with a CD38-/low were enriched in treated patients, which strengthens the NK cell 
fratricide theory (Wang, Zhang et al. 2018). This in combination with the high numbers of 
anti-inflammatory myelomonocytes possibly leads to a decrease in ADCC-mediated anti-
tumor activity that sustains during treatment.  
 
While the amount of activated NK cells before treatment has a positive effect on the 
response, the combination of Dara with adoptive NK cell transfer could have very favorable 
synergies. An alternating treatment of Dara with NK cells could keep antibody levels high. 
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With each adoptive transfer, fresh activated NK cells would then be able to clear the 
remaining MM cells. 
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3.2 STUDY II 
 
Infectious complications and NK cell depletion following daratumumab 
treatment of Multiple Myeloma 
 
 
Background 
 
MM is a plasma cell disease that is incurable, although new treatment methods like IMiDs 
or PIs have increased survival time drastically over the last decade. The monoclonal antibody 
Dara approved in 2015 by the U.S. FDA, is targeting CD38 on malignant plasma cells and 
shows very promising results in 36% of the patients (Lokhorst, Plesner et al. 2015). 
Additionally, it is the only single-agent treatment which shows the decrease of M-
component, which is a surrogate marker for disease progression (Lokhorst, Plesner et al. 
2015).  
 
However, we and others have shown that lymphocyte counts, and especially NK cell counts, 
will drop after administering Dara, which leaves the patient at risk for viral reactivation or 
new infections with bacteria or viruses (Alici, Chrobok et al. 2016, Lonial, Weiss et al. 2016, 
Usmani, Weiss et al. 2016). Specifically, the numbers of CD38+ NK cells will decline together 
with an oligoclonality of both CD4+ and CD8+ T cells which consequently leads to an 
impaired innate and adaptive immune system that is not able to maintain an effective antiviral 
defense (Mariani, Coscia et al. 2001, Krejcik, Casneuf et al. 2016). 
 
It is known that infectious complications are one of the leading causes of mortality in MM 
patients, particularly herpes zoster infections and CMV (Marchesi, Mengarelli et al. 2014, 
Blimark, Holmberg et al. 2015, Hasegawa, Aisa et al. 2016). The cause of this is multifactorial 
and involves inherited immune defects, therapy-related weakening of the immune system 
and unknown factors due to the interaction of the patients’ immune system with novel 
treatments like IMiDs (Teh, Harrison et al. 2016).  
 
 
Aim of the study 
 
In this study, we monitored the immune status of 23 patients that were included in a 
compassionate use program and treated with Dara. Nine out of the 23 suffered from either 
viral or bacterial infections or a combination of both. All patients had several lines of 
treatments before initiation of Dara as single-agent treatment. We observed clinical 
parameters as well as phenotypic markers, that were obtained by flow cytometry, in order 
to be able to find a link between immune status of the patient and infectious complication. 
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Results 
 
The patients that were admitted for this study all had progressing MM and were heavily 
pretreated with multiple lines of treatment such as IMiDs, PIs, chemotherapy, allogeneic or 
autologous stem cell transplantation and did not have any alternative treatments left. 
Admission criteria of the patients were similar as for the phase II trial as described by Lonial 
et al. except for also excluding patients with a creatinine clearance <20ml/min (Lonial, Weiss 
et al. 2016).  
 
The weekly Dara infusion schedule was at a starting dose of 16mg/kg body weight for eight 
weeks followed by a biweekly infusion for sixteen weeks and subsequent monthly infusions. 
Blood samples were taken prior to the first Dara infusion and successively after each 
following infusion if the health status of the patients allowed. Peripheral blood mononuclear 
cells were isolated and later analyzed by multicolor flow cytometry for NK and T cell 
subsets.  
 
Out of the 23 treated patients, fourteen showed a response to treatment, which is 
comparable to previously described studies (Palumbo, Chanan-Khan et al. 2016). Although 
the response rate was high we could observe infections in nine patients, two from bacterial 
infections only, five from viral infections and two from both viral and bacterial infections. 
Interestingly, none of the patients that achieved complete remission suffered from any kind 
of infection.  
 
As already described in study I, even in this study we could observe that NK cell counts 
dropped in all patients immediately after Dara infusion. This happened as fast as 24 hours 
after infusion and lasted over the time of Dara infusion. We could however not observe a 
recovery to normal NK cell levels (between 5 – 15 % of peripheral blood lymphocytes) in 
any of the patients. Another interesting observation was that the percentage of 
NKG2A+CD16+, which have a more immature phenotype, increased in some patients or 
were at least stable compared to the total lymphocyte count. Additionally, we followed the 
C-reactive protein (CRP) levels as well as total white blood cell counts (WBC) for all 
patients. CRP, which is a response marker for acute inflammation, correlates with the 
infection and is thus elevated. For some patients, we could observe a peak in CRP even 
before the infection was diagnosed which could have been caused by a bystander infection 
or an earlier infection/reactivation date that was clinically not yet linked to the infection.  
 
Out of the 23 patients, two were included in a study where they received allo-SCT prior to 
Dara infusion. One of the two suffered from a varicella-zoster virus (VZV) reactivation seven 
weeks after the first dose of Dara was administered. Blood samples from this patient were 
not available at first Dara infusion, but from the time of sampling (week two) NK cell 
percentage was already low and decreased even further prior to the VZV reactivation. 
Interestingly, also the ratio of CD4+ to CD8+ T cells decreased in the weeks before the 
reactivation, which in general means that the patient has an accumulation of pro-
inflammatory T cells and an impaired immune system.  
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The second patient did not suffer from any infection or latent reactivations during treatment 
but received two allo-SCT from a sibling donor. The WBC increased dramatically after the 
second allo-SCT together with the CRP. Remarkably, the distribution of CD4+ to CD8+ T 
cells inverted two times in correspondence to the two transplantations. Five weeks after 
the Dara infusion, the ratio decreased from 2.45 down to 0.44 and consequently increased 
again to reach 3.5 at ten weeks after the first infusion. It stayed at this high level even after 
the second transplantation and then reversed again 47 weeks after the first Dara infusion.  
 
 
Significance 
 
In study II we could show that patients who are treated with Dara have a higher risk to 
suffer from a primary viral or bacterial infection and that reactivation of latent viral infections 
is also increased. Due to the immunocompromised status of the patients, those infectious 
complications are potentially deadly. Close monitoring together with antiviral prophylaxis 
and adoptive NK cell therapy could overcome those problems.  
 
The main cause of death for MM patients is infections. In a recent study it was shown that 
myeloma patients have a seven-fold higher risk for bacterial infection and a ten-fold higher 
risk for viral infections compared to sex- and age-matched healthy individuals; and 22% of 
deaths in MM patients are caused by infections (Blimark, Holmberg et al. 2015, Terpos, 
Kleber et al. 2015). To some extent, susceptibility to infections results from the myeloma 
itself, as the immune system is impaired due to B-cell dysfunction as well as functional 
abnormalities of dendritic, T and NK cells (Urashima, Ogata et al. 1996, Cook and Campbell 
1999, Castriconi, Cantoni et al. 2003, Lee, Lee et al. 2004, Pinzon-Charry, Maxwell et al. 
2005, Beyer, Kochanek et al. 2006, El-Sherbiny, Meade et al. 2007, Tete, Bijl et al. 2014). In 
addition, therapy-related factors can also play a role as well as age-related frailty and physical 
dysfunctions, making the patient more susceptible to infections (Nucci and Anaissie 2009, 
Kleber, Ihorst et al. 2013). Keeping the infectious complications in patients under control is 
key for longer survival and better treatment outcome.  
 
Dara, which is an anti-CD38 humanized antibody, has direct and indirect effects on MM 
cells. One of the most important anti-tumor mechanisms is Dara-mediated ADCC. Once 
Dara binds to CD38 on the MM cells, NK cells are able to exert ADCC and lyse the tumor 
cells. NK cells, as well as many other cell types, express CD38 in low to intermediate levels, 
and upon activation CD38 expression is upregulated (Sconocchia, Titus et al. 1999, Funaro, 
Ferrero et al. 2000). However, we and others have published that CD38 expressing immune 
cells are depleted immediately after the first Dara infusion (Blimark, Holmberg et al. 2015, 
Alici, Chrobok et al. 2016, Krejcik, Casneuf et al. 2016, Casneuf, Xu et al. 2017).  
NK cells are among the first responders to viral infections as well as to malignant 
transformation of cells. Dara-induced depletion leads to a lack of this cell population which 
is associated with repeated infections (Orange 2002). In this study, nine out of the 23 
patients had infectious complication, five of which were reactivations with members of the 
herpesvirus family. In a recent publication, it was shown that after ASCT the rate of 
symptomatic CMV infection ranges between 0.7% to 30.7% (Marchesi, Pimpinelli et al. 2018). 
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Additionally, it is known that Bort as part of the MM treatment is associated with a higher 
incidence of CMV reactivation (Hasegawa, Aisa et al. 2016). 
  
However, two big clinical trials (POLLUX & ALCYONE) comparing Dara treatment with 
len-dex and bort-melphalan-prednisone respectively could not observe any CMV infections 
(Dimopoulos, San-Miguel et al. 2018, Mateos, Dimopoulos et al. 2018).  
 
Nevertheless, three patients in this study were identified for reactivation with CMV. In one 
of them, the infection was resolved without further treatment after a short Dara treatment 
interruption. It is not unlikely that CMV reactivation resolves itself in patients with 
hematological diseases unless they have undergone an allo-SCT (Styczynski 2018). 
  
One patient, who was without antiviral prophylaxis, eventually died of a Herpes Simplex 
virus (HSV) reactivation, despite antiviral treatment. This was not seen in any of the trials 
before and might be due to recommended antiviral prophylaxis in RRMM patients. The use 
of prophylaxis could conceal the number of HSV or VZV reactivation in those patients. 
Immune response against HSV is complex and both the innate and adaptive immunes system 
are involved in controlling the infection. Especially the role of NK cells in HSV infections is 
controversial as discussed in several papers, and at least for mouse models it might depend 
heavily on the site of infection and the mouse strain (Habu, Akamatsu et al. 1984, Bukowski 
and Welsh 1986, Pereira, Scalzo et al. 2001, Dai and Caligiuri 2018).  
 
Interestingly, we could observe that in three patients that showed reactivation from 
herpesviruses (CMV, HSV, VZV) the ratio between CD4+ and CD8+ T cells was very low. 
In a healthy individual, the ratio between CD4/CD8 ranges between 1.5 - 2.5 and a ratio 
>1.0 is associated with an impaired immune system due to chronic inflammation or infection 
(Bruno, Saracino et al. 2017). One possible explanation could be the depletion of CD38+ 
Tregs due to Dara-mediated ADCC which would reduce the total number of CD4 expressing 
T cells (Krejcik, Casneuf et al. 2016). Because of limitations in our flow cytometry panel, we 
could not assess CD38+ Treg counts and it is thus also just speculation if the ratio resulted 
from an expansion of CD8+ or the depletion of CD4+ cells. 
  
Recent publications have found an adaptive subtype of NK cells, described as 
CD57+NKG2C+, which distinguishes them from regular NK cells. The presence of those 
cells, their rapid expansion and high specificity to the virus correlates with the CMV infection 
(Guma, Budt et al. 2006, Lopez-Verges, Milush et al. 2011, Hendricks, Balfour et al. 2014). 
Interestingly, in two out of three patients that showed CMV reactivation, we could not 
observe an increase in adaptive NK cells with the aforementioned phenotype. 
 
In an 82y male, CMV reactivation could be detected just two weeks after the first Dara 
administration. This short time period together with the very low NK cell count after the 
first Dara infusion might be the reason why we could not observe any expansion of NK cells 
with an adaptive phenotype. This patient also had very high CRP levels directly before CMV 
reactivation and a slight decrease in mature NK cells that were able to exert ADCC (CD16+ 
NK cells). In parallel, 
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mature phenotype (NKG2A+CD16-). This shift from a more mature NK cell population to 
a less mature one was also observed by Rick Childs’ group in an in-vitro experiment in 2015 
(Cherkasova, Espinoza et al. 2015). When NK cells were sorted into CD16+ and CD16- 
fractions by FACS, only CD16+ NK cells were killed by Dara; no effect on CD16- population 
could be observed. Another recent case report by Frerichs et al. also reported a CMV 
reactivation in a heavily pretreated MM patient after Dara treatment. The reactivation is 
thought to have been caused by very low CD4+ T cells counts as well as drastically reduced 
levels of B and NK cell levels, which might be a combinational result of pretreatment and 
Dara treatment (Frerichs, Bosman et al. 2019).  
 
In this study, we could confirm what we published in study I: NK cells are specifically 
depleted upon Dara treatment. This results in a higher susceptibility for viral reactivations. 
As NK cells are one of the first-line defense mechanisms for infections, a synergistic adoptive 
NK cell therapy could lead to a better anti-myeloma treatment outcome and potentially 
reduce the risk for infections.  
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3.3 STUDY III 
 
Functional Assessment for Clinical Use of Serum-Free Adapted NK-92 Cells 
 
 
Background 
 
Using adoptive cell transfer as a treatment for cancer has been practice since the first stem 
cell transplantations and has evolved dramatically since then. Especially in the last few years, 
more and more effort has been made in developing a more targeted therapy approach 
aiming at higher efficacy and fewer side effects and risks than the traditional treatments. 
 
With the development of the CD19 CAR against B cell-derived malignancies, the 
combination of cell-based therapy and genetically modifying cells has been brought to the 
next level (Maude, Frey et al. 2014, Kochenderfer, Dudley et al. 2015). Not only several 
new targets are currently being developed to make use of those genetically modified cells, 
but also ex-vivo expanded or activated T or NK cells are widely being tested for several 
indications (Sutlu and Alici 2009, Dahlberg, Sarhan et al. 2015). One of the most pivotal 
components for successful cell expansion for clinical applications is human serum. All other 
components (media, cytokines, chemicals etc.) are available as chemically defined with a 
CGMP certificate. However, serum is also one of the key drivers for successful expansion 
and has a huge impact on fold expansion or composition of the final cell product. The other 
critical part is the source of the cells; allogeneic and autologous cells both have their 
advantages and disadvantages for certain cancer indications.  
 
The uses of irradiated cytotoxic NK cell line for adoptive therapy has been explored by 
several groups and so far, the results have been promising (Gong, Maki et al. 1994, Arai, 
Meagher et al. 2008, Tonn, Schwabe et al. 2013, Nowakowska, Romanski et al. 2018). When 
trying to create an “off-the-shelf” product, serum dependency is still a big hurdle and cells 
grown under fully defined conditions would have a more predictable outcome in terms of 
cell proliferation, cytotoxicity and phenotype.  
 
 
Aim of the study 
 
In this study, we investigated if NK-92 cells can be grown serum free with inherited 
phenotype and antitumor responses. Critical steps included culturing these cells for long 
term and being able to repeatedly freeze and thaw them. Additionally, we compared the 
transcription profile of serum free and serum complemented cells and explored 
susceptibility to genetic modifications.  
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Results 
 
We gradually decreased the serum concentration from initially 20% to 0% in the culture 
conditions over the course of three weeks, followed by a three-week recovery period. 
While NK-92 grow in spheres in regular culture conditions, they lose this growing habit 
once the serum is gradually reduced, probably due to stress by the low serum levels. After 
a short three-week recovery period the cells grow at a comparable tempo and also spheres 
can be observed again. We could show that long term culture, up to several months, under 
serum-free conditions is possible and that serum-free NK-92 cells don’t show higher 
apoptotic cell percentage during culturing. In order to be able to compare the cells from 
both culture conditions, we assessed the phenotype of the activating and adhesion receptors 
in a flow-based assay. We could not determine any significant difference. Although the 
phenotype wasn’t altered, we could observe a decrease in functionality in a standard four-
hour chromium release assay as well as in a degranulation assay against the target cell line 
K562.  
 
The load of the NK-92 cells with the cytotoxic molecules granzyme A & B and perforin was 
comparable although the total load varied between different batches. However, if those cells 
were used for a therapeutic approach they would be infused to a patient and by that have 
contact with serum again. To simulate this condition, we added serum to the serum-free 
culture for 16 hours and performed the same functional assays. We could then observe that 
the decreased cell lysis of K562 cells was reversed and comparable to serum-supplemented 
culture. 
 
To get better insights into the biological mechanism that plays a role in adaption to serum-
free culture conditions we performed RNA sequencing. We observed that especially the 
genes of the antigen presenting pathway were upregulated in serum-free cultured NK-92 
cells. Also, genes related to MHC class I, as well as interferon-stimulated genes and MYC 
were elevated. Interestingly, the change in expression levels seems to be most prominent 
in the step between 5% to 0% serum. Lastly, we also showed that repeated freeze and thaw 
cycles are well tolerated by serum-free cultured NK-92 cells without an increase in 
apoptosis or decrease in functionality.  
 
 
Significance 
 
In this study, we adapted NK-92 cells to long term serum-free culture conditions which 
showed an inherited phenotype and comparable doubling times. Although functionality 
towards K562 is decreased under serum-free conditions, we could observe that 
reintroduction of serum reverses the effect and leads to equivalent killing, compared to 
serum-cultured NK-92. This culturing method is an affordable expansion procedure for 
clinically grade NK-92 cells and is as feasible as current standard clinical manufacturing 
protocols. 
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NK cells obtained from patients with progressing cancer are mostly hypo-responsive toward 
the autologous tumor cells. If those primary NK cells are expanded and activated ex-vivo in 
the absence of the tumor, their functionality and ability to recognize autologous tumor cells 
can be restored. One of the biggest hurdles is achieving sufficient cell numbers with the 
desired phenotype. Not all expansion yields cell numbers that are necessary for clinical 
application and this not only depends on the cell source but largely on the serum. As neither 
human serum nor fetal calf serum is chemically defined and can vary widely in the levels of 
hormones, lipids, and proteins, the impact on a particular cell type might be enormous. 
Finding the right serum for one specific cell type and one specific way of culturing cells can 
be time-consuming and costly. For example, a growth factor for one cell type could cause 
differentiation in another cell type; or the exposure of female-derived PBMCs to 
testosterone could induce dramatic functional changes (Moscovis, Cox et al. 2015).  
 
Lately, research groups have focused more and more on the impact of extracellular vehicles 
(EVs) and their impact on cell to cell communications. Among other functions, EVs can be 
internalized by cells and deliver their cargo such as mRNA, miRNA, and rRNA and thus 
have a direct impact on intercellular signaling (Shelke, Lasser et al. 2014). Serum contains 
large amounts of EVs, which have a significant impact on the growth and behavior of cultured 
cells (Eitan, Zhang et al. 2015, Wei, Batagov et al. 2016). Although sera from several donors 
are pooled together during clinical grade serum production to minimize the impact of each 
component, variation between each batch is high and has a direct impact on the final cell 
product.  
 
Reproducing results and achieving a consistent product across research groups and 
production facilities is difficult to accomplish. This is due in part to differences in assay 
protocols, cell models or just equipment, which can be changed and optimized, but also due 
to undefined components such as serum. It is not only necessary to conduct a pre-screening 
of several different batches but also to acquire large enough batch sizes for long term 
studies, which is challenging. All in all, a fully-defined cell expansion system is in many factors 
superior compared to a system that heavily relies on non-defined components such as 
serum.  
 
Using a cell line for therapy has the advantage that the production is scalable and predictable 
numbers of highly cytotoxic cells are easily obtained without a biological donor variation. 
As described in the study, it could be observed that serum-free cultured NK-92 cells show 
a lower cytotoxic capacity, but we could also show that over-night exposure to serum could 
restore the cytotoxicity of the cells. This reintroduction would mimic a possible infusion 
scenario where bedside thawed, irradiated serum-free grown NK-92 were administered 
into a patient and would thus come into contact with serum, which might boost their 
cytotoxic capacity.  
 
Several clinical trials are currently ongoing, which use the NK-92 cell line either just 
activated and unmodified or modified. One way of modification is using a CAR e.g. against 
HER2, CD19 another option is expressing CD16 so that the combination with a mAb 
treatment is possible (Nowakowska, Romanski et al. 2018, Tang, Yang et al. 2018, Tomalka, 
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Resto-Garay et al. 2018, Zhang, Zhang et al. 2018). The following studies are currently 
recruiting for either solid tumors or hematological malignancies: NCT03383978, 
NCT03656705, NCT03027128, NCT02892695, NCT03563170, NCT03586869 (from 
clinicaltrials.gov); several more have also already been announced.  
 
With the culture method described in study III we could show that NK-92 cells are able to 
grow under serum-free, chemically-defined media conditions with only the addition of IL-2. 
Adapting this robust and affordable expansion procedure for future clinical trials could 
decrease manufacturing costs and eliminate the variation of serum batch to batch variation.  
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4 CONCLUDING REMARKS AND FUTURE 
PERSPECTIVE 
 
With the clinical approval of the first CAR T cells products, YESCARTA and KYMRIAH in 
2017 and 2018 respectively, and remarkable results in B cell lymphoma, immunotherapy 
moved into the focus of not only scientists and clinicians but also the general public. 
 
Dara, as the first approved mAb for MM treatment, had breakthrough success and gave new 
hope to relapsed/refractory patients. Prolongation of life and better disease control even in 
heavily pretreated patients are key features of this treatment. Over the last decade countless 
research groups helped understand the impact of the immune system in MM and specifically 
the role of NK cells. We and others showed that ex-vivo expanded NK cells have significant 
cytotoxicity against autologous MM cells without targeting healthy tissue. These findings 
make NK cells an optimal source for NK cell-based adoptive therapy. Several trials have 
explored this treatment option with NK cells from various sources.  
 
However, with the first Dara treated patients it has become clear that despite the huge 
treatment related success there are also drawbacks and side effects with this treatment. NK 
cells and partly other CD38 expressing immune cells are depleted after Dara administration, 
which can lead to an increased risk for viral and bacterial infections. This is especially 
important because one of Dara’s main mechanisms of action is NK cell-mediated ADCC. 
The reduced pool of effective NK cells might lead to a possible reduction of Dara 
effectiveness.  
 
Combining Dara treatment with adoptive NK cell treatment could have a positive synergistic 
effect on MM disease control. Alternating infusing expanded, activated NK cells with Dara, 
would keep cytotoxic levels of NK cells high and boost the effect Dara has on fighting MM.  
 
Various sources can be used to obtain sufficient numbers of highly active NK cells. Using a 
cell line which combines characteristics of an NK cell (cytotoxicity and cytokine production) 
with that of a tumor cell (limitless proliferation potential) has the advantage of predictable, 
functional active, “off-the-shelf” cells being easily producible.  
 
For streamlined NK cell production, biological variation and undefined expansion 
components are problematic. Adapting NK-92 as a model cell line, and later primary NK 
cells to serum-free culture conditions, eliminates the batch to batch variation of the 
chemically undefined serum. Combining a defined, robust expansion protocol to obtain 
clinical grade NK cells for adoptive therapy in combination with mAb treatment could be a 
breakthrough for future treatment regimens.  
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